Plasma Fractionation Market Overview
Plasma fractionation is a method used for segregating plasma into its different components. Proteins present in plasma are mainly used for therapeutic purposes in the treatment of various diseases. Factors primarily responsible for the growth of the global plasma fractionation market are increased prevalence of rare diseases, surge in geriatric population, and growing use of immunoglobulins in different therapeutic domains.
On the basis of product type, the plasma fractionation market is categorized into immunoglobulins, coagulation factors, albumins, and protein inhibitors, wherein immunoglobulins hold the largest revenue share in the market. This is attributed to the rising prevalence of primary immunodeficiency disease (PIDD). For instance, treatment of PIDD is mainly dependent upon regular infusion therapy where immunoglobulins are involved in the treatment procedure. The market for albumins is expected to observe the fastest growth, owing to rapid use of the products in various drug formulations, especially for drugs used in treatment of acute liver diseases.
In the plasma fractionation market, laboratories, hospitals, and academic institutes are the prime end users. In 2018, hospitals are estimated to be the largest end-user category in the market, characterized by the availability of large and sophisticated devices; and presence of skilled professionals. Presence of different operating rooms and diagnosis facility in hospitals are predicted to boost the growth of the market for this category. This is due to the fact that a large number of equipment for testing and analysis are required in the hospitals.
Based on application, the plasma fractionation market is classified into neurology, immunology, hematology, pulmonology, and rheumatology. Among all the application areas, plasma fractionation products are majorly used in neurology, due to high prevalence of neurological disorders. Moreover, successful results have been obtained by the use of intravenous immunoglobulins for the treatment of neurological diseases.
On the basis of geography, the plasma fractionation market is categorized into North America, Asia-Pacific, Latin America, Europe, and Middle East and Africa. In 2017, North America held the largest market share in terms of revenue, globally, owing to the rising prevalence of various chronic diseases. According to the World Health Organization (WHO), percentage of global daily-adjusted life years (DALYs) for neurological disorders is predicted to increase from 6.39% in 2015 to 6.77% by 2030. Moreover, Centers of Diseases Control and Prevention (CDC) reports a fact that about 400 babies are born with hemophilia A each year. These increase the demand for plasma fractionation products, thereby driving the market growth in the coming years.
Plasma Fractionation Market Dynamics
Growth Drivers and Restraints
The major growth driver for the plasma fractionation industry is the rising number of patients suffering from rare autoimmune diseases. According to the facts stated by National Institute of Environmental Health Sciences (NIEHS) in 2018, rare autoimmune diseases affect more than 23.5 million people in the U.S. Moreover, NIEHS also supports various clinical research institutes on how immunity and environmental factors work together to compromise the body’s ability to defend itself, and develop into autoimmune diseases. For instance, National Toxicology Program (NTP) by NIEHS is involved in researching on the link between genetic predisposition and environmental triggers.
Rising prevalence rate of immunodeficiency diseases also serves as a key driving factor for the plasma fractionation market growth. PIDD, multiple sclerosis, and immune thrombocytopenia purpura (ITP) are some of the examples of rare immune diseases that have high prevalence rate, globally. According to the reports by Immune Deficiency Foundation (IDF), in 2018, there were approximately 250,000 people diagnosed with PIDD.
However, high cost of plasma fractionation procedures, availability of recombinant technology as a substitute, and stringent regulations are some factors that restrain the growth of the plasma fractionation market.
Plasma Fractionation Market Competitive Landscape
Key market players are focusing on the development of highly improved and technologically advanced products, to increase their share in the global plasma fractionation market. For instance, in December 2018, Novo Nordisk attained U.S. Food and Drug Administration (USFDA) approval for Novoeight, a drug manufactured by plasma fractionation method. This drug is used to treat patients suffering from hemophilia A.
Some of the other players operating in the plasma fractionation industry are CSL Behring, Japan Blood Products Organization, Green Cross Corp., Bio Product Laboratory Ltd., Octapharma AG, Kedrion S.p.A., and Grifols International S.A.
The study provides the historical as well the forecast market size data for various countries including the U.S., Canada, France, Germany, the U.K., Italy, Spain, Japan, China, India, Brazil, Saudi Arabia, and South Africa.